Clinnova-MS
Improving personalised care for people living with multiple sclerosis through health data and AI
Multiple sclerosis (MS) is a chronic neurological condition that can affect people in very different ways. While many treatments are available to reduce relapses and inflammation, it remains difficult to predict how the disease will progress in each individual and which treatment will be most effective over time. The Clinnova-MS project aims to improve personalised care for people living with MS. By combining clinical information with imaging, biological, digital, and patient-reported data, researchers hope to identify markers that can help predict disease activity, such as relapses or progression, and better understand how patients respond to different treatments. Using advanced data science and artificial intelligence, the project will explore how information collected during routine care and research can be used to support more individualised treatment decisions and improve disease monitoring. Researchers also aim to gain new insights into the biological mechanisms underlying disease progression and treatment response. In the long term, Clinnova-MS seeks to contribute to a more personalised, preventive, and data-driven approach to MS care, helping healthcare professionals make more informed decisions and improve outcomes for people living with MS.
Clinnova-MS is part of the Clinnova programme
About the study
Locations
L-1210 Luxembourg
Contact
Want to learn more?
Who can participate?
Eligible participants
Clinnova-MS is recruiting patients with early MS, transitioning to progressive disease, or undergoing treatment change. Specifically, you may be eligible to participate if you:
- Are 18 years of age or older.
- Have been diagnosed with multiple sclerosis (MS), including all its clinical forms (clinically isolated syndrome, relapsing-remitting MS, secondary progressive MS, or primary progressive MS).
- Are in the early stages of MS (within 3 years of diagnosis), or are experiencing a significant change in your disease or treatment, such as a relapse, treatment change, or progression of symptoms.
- Are willing and able to attend study visits, complete study assessments, and provide the required data and biological samples.
- Are able to understand the study information and provide written informed consent.
Exclusion criteria
You may not be eligible to participate if you:
- Do not have a confirmed diagnosis of multiple sclerosis.
- Have a condition that would make it difficult to take part in the study procedures or attend study visits.
- Are not fluent in French, English, or German.
- Are currently pregnant.
Not sure about eligibility?
The study team will review each case individually to determine eligibility. If you are unsure whether you are eligible, do not hesitate to contact us.
What will participants do?
01.
Attend study visits
These will take place at the start of the study, after 6 months, and after 12 months during the first year.
02.
Provide health and lifestyle information
This will include demographic information, medical data, laboratory results, and physical examination data.
03.
Complete questionnaires and study tasks
These will be completed between visits using the dreaMS app to help researchers understand your symptoms, daily experiences, and quality of life.
04.
Provide biological samples
- Blood samples (mandatory)
- Saliva, urine, stool, cerebrospinal fluid (CSF), and hair samples (optional)
05.
Allow the use of imaging and tissue samples
This applies if these are collected as part of your routine medical care.
06.
Attend an additional study visit if needed
This may be required if you experience a relapse, flare, or important treatment change.
02.
Take part in long-term follow-up
This may continue for up to 5 years and will include: yearly collection of medical data, questionnaires every 6 months, and continuous smartwatch data collection.
Contact & location
Centre Hospitalier de Luxembourg – CHL Centre
4 rue Barblé
L-1210 Luxembourg
Study team
Prof. Dr Rejko Krüger
Coordinator, National Centre for Excellence in Research on Parkinson’s disease (NCER-PD); Director of Neurology, Luxembourg Research Clinic (LRC), Luxembourg Institute of Health (LIH); Neurologist and Medical coordinator, Réseau de Compétences Maladies Neurodégénératives, Centre Hospitalier de Luxembourg (CHL); Professor for Clinical and Experimental Neuroscience, University of Luxembourg (UL)
Centre Hospitalier de Luxembourg (CHL)
Participating institutions
Clinnova-MS is a collaboration between more than 25 clinical and research partners across Luxembourg, Switzerland, France, and Germany. Participating institutions in Luxembourg include:
Funded by
Luxembourg National Research Fund (FNR)
Want to learn more about the study?
Visit the website for full study details, scientific publications and research background.
Related news & updates
Small country, significant capacity
Luxembourg may be one of Europe’s smallest countries, but the Luxembourg Research Clinic demonstrates how its highly connected national network…
Clinnova Consortium Agreement signed, marking a major milestone for health research across Europe
Thanks to a joint investment from LIH and the Ministry of Health, the national biobank accessible to LRC studies has…
Building on Luxembourg’s Research Strengths
The Luxembourg Research Clinic brings together the strengths of Luxembourg’s leading healthcare, research and academic institutions, building on established expertise…
Landmark agreement ensures sustainability of Luxembourg Parkinson’s programme
Three leading researchers have joined the LRC's scientific committee, bringing expertise in immunology, rare diseases, and translational genomics from institutions…
Related events
Clinical Research Luxembourg Conference
Why does clinical research matter today in Luxembourg? Clinical research plays a vital role in improving patient care, driving medical…